Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2022-12-30 00:00:00 ET · period of report 2022-12-29 · accession 0000902664-22-005341 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-12-30 | 2022-12-29 | LAB | Caligan Partners LP | 10% | J - Other | — | -2.87M | 8.58M | -25% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.001 par value per share (Common Stock) | 2022-12-29 | J | D | 2,868,037 | — | 8,576,799 | I See footnote | — | — | (F1) This transaction represents an in-kind distribution by certain funds and accounts to which Caligan Partners LP ("Caligan") serves as the investment manager. (F2) The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |